Laddar populära aktier...
Organic growth of 11% vs. cons. 10% Adj. EBITA SEK 128m, 13% below consensus Gross margin recovery i...
Slutlig studiedesign närmar sig Medivir har fullt fokus på att ta fostrox framåt mot en registrering...
Redeye comments on Freemelt’s new order from UKAEA, which deepens Freemelt’s position within the fus...
Q1: Clean EBIT of SEK 5m, production issues Pulp prices move higher, demand stronger Fair value rang...
Q1'24 results due 7 May '24e-'26e EBIT up 0.8-1.6% due to FX 29-39% below historical NTM P/E and NTM...
Redeye reviews Medivir's fourth quarter report, which presented another improvement of median time t...
Redeye endorses that CLS’ partner, ClearPoint Neuro, has received FDA (510k) clearance for its Prism...
Sales -10% vs. ABGSCe, but EBIT in line at SEK 0m New customer signings in NW&FT and GC&MP to grow s...
Loihde’s Q1 was a pleasant surprise, as we had expected a softer start to the year.
Redeye update on Embracer ahead of Q4-results (due 23 May) where we also adjust our estimates follow...
Solteq’s Q1 results were slightly weaker than expected and revenue declined slightly y/y in comparab...
Aktieanalytiker Mathias Carlson intervjuar VD Torbjörn Saxmo efter publicerad Q1-rapport.
- More positive news for Scandpower - Profitability has always been volatile - Minor revisions with ...
- Slowdown in Q2 before acceleration occurs in H2'24 - 23% adj.
- Quarterly miss brings down CEPS 2024e by -4% - Awaiting news on Polish acquisition agenda - Share ...